摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

多亚甲基多苯基多异氰酸酯 | 9016-87-9

中文名称
多亚甲基多苯基多异氰酸酯
中文别名
聚[(异氰酸苯酯)-co-甲醛];PAPI
英文名称
Formaldehyde;isocyanatobenzene
英文别名
——
多亚甲基多苯基多异氰酸酯化学式
CAS
9016-87-9
化学式
C8H7NO2
mdl
——
分子量
149.15
InChiKey
JTEOXXUIKUHXLD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    392 °C5 mm Hg
  • 密度:
    1.2 g/mL at 25 °C(lit.)
  • 蒸气密度:
    8.6 (vs air)
  • 闪点:
    >230 °F
  • 溶解度:
    可溶于DMSO(少量)、乙酸乙酯(少量)、甲醇(水中的溶解度为)
  • 物理描述:
    Polymeric diphenylmethane diisocyanate is a dark-brown liquid with a weak odor. Sinks in water. (USCG, 1999)
  • 颜色/状态:
    DARK-AMBER VISCOUS LIQUID
  • 熔点:
    200°C
  • 蒸汽压力:
    LESS THAN 1X10-4 MM HG @ 25 °C
  • 稳定性/保质期:
    在常温常压下保持稳定,应避免接触强氧化剂。

计算性质

  • 辛醇/水分配系数(LogP):
    1.47
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    46.5
  • 氢给体数:
    0
  • 氢受体数:
    3

ADMET

毒理性
  • 致癌性证据
没有关于人类的数据。没有关于动物的数据。总体评估:第3组:该物质无法归类为对人类的致癌性。
No data are available in humans. No data are available in animals. OVERALL EVALUATION: Group 3: The agent is not classifiable as to its carcinogenicity to humans.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 致癌性证据
证据权重特征描述:根据美国环保局1996年的致癌风险评估指南,单体MDI或聚合物MDI(PMDI)将被分类为不可分类或D组化学物质。根据美国环保局1996年提出的致癌风险评估指南,MDI/PMDI的致癌潜力将被描述为“无法确定,但有提示性证据引起对致癌效果的担忧”,基于以下原因。在一项涉及PMDI的终身慢性吸入研究中,暴露于最高浓度的雄性(6/60)和雌性(2/59)Wistar大鼠(品系Cpu:WU)中肺腺瘤的发生率增加,以及一只雄性大鼠中出现一例肺腺癌,这表明PMDI具有肿瘤发生潜力。然而,肿瘤发生结果与证据相结合,表明亚甲基二苯基苯胺(MDA),一种已知的动物致癌物和MDI的主要反应产物,在MDI暴露大鼠的血液中和PMDI/MDI暴露人类的非水解尿液中发现了,这增加了对PMDI/MDI致癌潜力的担忧。现有的人类证据不足以描述PMDI/MDI的致癌潜力。人类致癌性数据:不足。动物致癌性数据:有限。
WEIGHT OF EVIDENCE CHARACTERIZATION: Under U.S. EPA's 1996 Guidelines for Carcinogenic Risk Assessment, monomeric MDI or polymeric MDI (PMDI) would be classified as not classifiable or a Group D chemical. Under U.S. EPA's 1996 Proposed Guidelines for Carcinogenic Risk Assessment, the carcinogenic potential of MDI/PMDI would be characterized as "cannot be determined, but for which there is suggestive evidence that raises concern for carcinogenic effects" on the following basis. The increased incidence of pulmonary adenomas in male (6/60) and female (2/59) Wistar rats [strain Cpu:WU] and one pulmonary adenocarcinoma in a male rat, all exposed to the highest concentration in a lifetime chronic inhalation study involving PMDI, suggest that PMDI has tumorigenic potential. However, the tumorigenic results, coupled with evidence that methylene diphenyl aniline (MDA) a known animal carcinogen and the principal reaction product of MDI, is found in blood of MDI-exposed rats and nonhydrolyzed urine of PMDI/MDI-exposed humans increases concern about the carcinogenic potential of PMDI/MDI. The available human evidence is inadequate to describe the carcinogenic potential of PMDI/MDI. HUMAN CARCINOGENICITY DATA: Inadequate. ANIMAL CARCINOGENICITY DATA: Limited.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 致癌性证据
美国环保局-柴油机
EPA-D
来源:Occupational Safety and Health Administration (OSHA)
毒理性
  • 健康影响
健康影响代码:HE9 - 除刺激外的心肺效应 - 呼吸道过敏(哮喘或其他)
Health Effect Code(s):HE9 - Respiratory Effects Other Than Irritation---Respiratory sensitization (asthma or other)
来源:Occupational Safety and Health Administration (OSHA)
毒理性
  • 毒性总结
识别和使用:聚亚甲基聚苯基异氰酸酯是一种深琥珀色的粘稠液体。它被用作颗粒板的粘合树脂和铸造砂芯的粘合树脂。人类暴露和毒性:异氰酸酯对皮肤和粘膜有刺激性,皮肤状况从局部瘙痒到广泛湿疹不等。眼部疾病较少见,流泪现象明显。结膜炎的发病率很低。异氰酸酯对肺部组织有严重影响。处于异氰酸酯不良反应风险中的人群包括有哮喘、过敏、肺或肺功能受损病史的人。致癌性证据:在人类中没有证据。动物研究:在一项终身慢性吸入研究中,雄性和雌性Wistar大鼠的肺部腺瘤增加。在工业报告中,五只白化病大鼠单次接触这种化学物质后出现流涎、鼻涕和异常黄色变色。大体解剖没有发现异常。通过口服灌胃给ChR-CD雄性大鼠单次剂量的聚亚甲基聚苯基异氰酸酯,大体解剖发现胃粘膜糜烂和增厚以及胃部肿块。显微组织病理学发现胸腺细胞减少、肝细胞空泡减少和肝脏局部炎症。家兔接受单次封闭涂抹未稀释的聚亚甲基聚苯基异氰酸酯,涂抹部位出现轻微皮肤红斑和轻微革质化。在解剖时没有观察到影响。白化病斯普拉格-道利大鼠通过吸入这种化学物质暴露后观察到肺充血。对Cpb:WU,Wistar随机大鼠通过吸入聚亚甲基聚苯基异氰酸酯进行的致癌性研究发现,死亡率与浓度呈负相关。影响包括嗅觉上皮的鲍曼腺基细胞增生和鲍曼腺增生,肺泡管上皮细胞,肺泡管纤维化在巨噬细胞积聚的周围组织中。肺重量增加,肺中钙化颗粒以及局限性支气管化和肺部腺瘤以及肺腺癌的增加。长期暴露于聚亚甲基聚苯基异氰酸酯蒸气的长埃文斯大鼠的临床观察包括呼吸困难的症状,如啰音。大体解剖没有发现处理变化。在鼠伤寒沙门氏菌测试菌株TA1535、TA1537和TA1538( Ames试验)中,无论是否进行代谢激活,都没有在任何测试的菌株中产生阳性结果。
IDENTIFICATION AND USES: Polymethylene polyphenyl isocyanate is a dark amber viscous liquid. It is used as a binder resin for particle board and as a foundry core binder resin. HUMAN EXPOSURE AND TOXICITY: Isocyanates are irritating to the skin and mucous membranes, the skin conditions range from localized itching to wide spread eczema. Eye affections are less common and lacrimation is noted. The incidence of conjunctivitis is rare. Isocyanates have serious effects on lung tissue. Individuals who are at risk from adverse effects of isocyanates include those with a history of asthma, allergies, impaired lung or pulmonary function. Evidence of Carcinogenicity: No evidence in humans. ANIMAL STUDIES: The increased in pulmonary adenomas in male and female Wistar rats were noted in a lifetime chronic inhalation study. In industry reports five albino rats exposed to this chemical by single doses exhibited salivation, nasal discharge and abnormal yellow discoloration. Gross necropsy revealed no abnormalities. ChR-CD male rats administered single doses of polymethylene polyphenyl isocyanate by oral gavage, gross necropsy revealed eroded and thickened stomach mucosa and masses in the stomach. Microscopic histopathology discovered depletion of thymocytes, reduced liver cell vacuolation and focal inflammation of the liver. Rabbits receiving single occluded applications of undiluted polymethylene polyphenyl isocyanate showed slight skin erythema and slight coriaceousness at the application site. No effects were observed at necropsy. Lung congestion was observed in Albino Spartan Sprague-Dawley rats exposed by inhalation to this chemical. A carcinogenicity study of polymethylene polyphenyl isocyanate in Cpb:WU, Wistar random rats exposed by inhalation showed mortality rates were negatively correlated with concentration. Effects included basal cell hyperplasia and hyperplasia of Bowman's glands in the olfactory epithelium of the nose, alveolar duct epithelia, alveolar duct fibrosis in tissues surrounding macrophage accumulations. Increases in lung weights along with calcerous particles in lungs and localized areas of bronchiolisation and pulmonary adenomas and a pulmonary adenocarcinoma were noted. In Long-Evans rats exposed by inhalation of polymethylene polyphenyl isocyanate vapors clinical observations included respiratory distress in the form of rales. Gross necropsy revealed no treatment changes. In Salmonella typhimurium tester strains TA1535, TA1537 and TA1538 (Ames test) with or without metabolic activation did not produce positive results in any strain tested.
来源:Hazardous Substances Data Bank (HSDB)

安全信息

  • 危险品标志:
    Xn
  • 安全说明:
    S26,S28,S38,S45
  • 危险类别码:
    R20
  • WGK Germany:
    3
  • 危险品运输编号:
    NONH for all modes of transport
  • 海关编码:
    3909301000
  • 危险类别:
    6.1
  • RTECS号:
    TR0350000
  • 包装等级:
    II

制备方法与用途

化学性质
这是一种褐色透明的液体,具有刺激性气味。

用途
该物质广泛用于制造泡沫塑料和粘合剂。此外,它还可用于生产聚氨酯材料,并在建筑行业、汽车工业及电器行业中作为保温材料或垫褥等应用。

生产方法
将苯胺与甲醛按摩尔比1.6-2.0:1的比例配合,再加入适量盐酸作为催化剂,在缩合器中于90-110℃条件下反应30-60分钟,得到一定比例的二苯基甲烷-4,4'-二胺和多次甲基多苯基甲胺。然后通过光气化、分离及提纯等步骤即可制得PAPI(聚合聚氨酯异氰酸酯)和MDI(多亚甲基多苯基异氰尿酸酯)。原料消耗定额为:甲醛(100%)150kg/t、苯胺750kg/t、光气850kg/t。

文献信息

  • Pyrithione compound and microcapsule using the same
    申请人:Sugai Masaharu
    公开号:US20050271736A1
    公开(公告)日:2005-12-08
    A compound represented by formula (I); a multifunctional isocyanate composition, containing an adduct formed by treating the compound represented by formula (I) with a compound represented by formula (II); and a microcapsule using the multifunctional isocyanate composition: wherein, in formula (I), R 1 represents -L 1 -X 1 or X 1 ; R 2 represents a hydrogen atom or -L 2 -X 2 ; L 1 and L 2 each independently represent a divalent linking group; X 1 and X 2 each independently represent a nucleophilic substituent; n represents an integer of 1 to 4; and when n is 2 or more, R 1 s may be the same or different; and R 3 —(NCO) m Formula (II) wherein, in formula (II), R 3 represents an arbitrary m-valent linking group; and m represents an integer of 2 or above.
    一种由化学式(I)表示的化合物;一种含有通过将化学式(I)表示的化合物与化学式(II)表示的化合物处理形成的加合物的多功能异氰酸酯组合物;以及使用多功能异氰酸酯组合物的微胶囊:其中,在化学式(I)中,R1表示-L1-X1或X1;R2表示氢原子或-L2-X2;L1和L2各自独立表示二价连接基团;X1和X2各自独立表示亲核取代基;n表示1到4之间的整数;当n为2或更多时,R1可以相同也可以不同;且R3—(NCO)m 化学式(II)其中,在化学式(II)中,R3表示任意m价连接基团;m表示2或以上的整数。
  • US7230110B2
    申请人:——
    公开号:US7230110B2
    公开(公告)日:2007-06-12
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐